MNTA  Momenta Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.05 (+0.35%)

Company Metrics

  • P/E 13.83
  • P/S 9.98
  • P/B 3.00
  • EPS -1.34
  • Cash ROIC -52.09%
  • Cash Ratio 9.03
  • Dividend 0 / N/A %
  • Avg. Vol. 572,080.00
  • Shares 68.96M
  • Market Cap. 979.19M

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


A New Kind of Stock Chart: Momenta Pharmaceuticals Inc (NASDAQ:MNTA) Critical ...
CML News - 2 hours ago
This is a real time view of the critical technical pivot points for Momenta Pharmaceuticals Inc (NASDAQ:MNTA) . The technical pivot points we look at all surround the stock price movement from the last 10-trading days through the last year.
Why Momenta Pharmaceuticals, Inc. Jumped Higher Today
Motley Fool - Oct 11, 2016
The Motley Fool recommends Momenta Pharmaceuticals and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days.
A Compelling Risk/Reward Seen In Momenta Pharmaceuticals - Benzinga
Momenta Pharmaceuticals (MNTA) Surges on Barclays Upgrade - Economic Calendar
Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales
Motley Fool - Nov 4, 2016
Momenta recorded $23.3 million in product revenues from its partner Novartis' (NYSE:NVS) sale of Glatopa, their generic version of Teva Pharmaceuticals' (NYSE:TEVA) once-daily multiple sclerosis drug Copaxone. That's an increase of over $2 million ...
Momenta Pharmaceuticals' (MNTA) Buy Rating Reaffirmed at Barclays PLC - Community Financial News
Momenta Pharmaceuticals' (MNTA) Buy Rating Reiterate at Barclays PLC - DailyQuint
Maxim Group Reiterates "$6.00" Price Target for Momenta Pharmaceuticals Inc ...
The Cerbat Gem - Dec 3, 2016
Momenta Pharmaceuticals Inc. logo Maxim Group set a $6.00 price objective on Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) in a research note released on Tuesday morning.
Momenta Pharmaceuticals Inc. (MNTA) Receives $16.00 Average PT from Analysts - Community Financial News
The Momenta Pharmaceuticals Inc. (MNTA) Receives Consensus Rating of “Buy ... - DailyQuint
Momenta Pharmaceuticals Inc. (MNTA) Receives $16.00 Consensus Target Price ...
Sports Perspectives - 6 hours ago
Momenta Pharmaceuticals logo Shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) have earned an average recommendation of “Buy” from the ten brokerages that are currently covering the stock.
Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February -- Here's Why
Motley Fool - Mar 4, 2016
What: Shares of Momenta Pharmaceuticals (NASDAQ:MNTA), a biopharmaceutical company focused on the development of generic and biosimilar drugs for oncology and autoimmune diseases, shed 33% of their value in February, based on data from S&P ...
Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Other Events
Market Exclusive - Nov 29, 2016
On November 29, 2016, Momenta Pharmaceuticals, Inc. (the “Company”) announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA® (adalimumab) candidate, in patients with moderate-to-severe chronic plaque psoriasis, met its ...
Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923 a ... - EconoTimes
Momenta's Humira biosimilar succeeds in key psoriasis study - Reuters
Momenta Pharmaceuticals Inc. (MNTA) Coverage Initiated by Analysts at Aegis
The Cerbat Gem - Nov 23, 2016
Momenta Pharmaceuticals Inc. logo Aegis assumed coverage on shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) in a research note published on Tuesday morning.
Momenta Pharmaceuticals Inc. (MNTA) CFO Richard P. Shea Sells 971 Shares of Stock - Community Financial News
Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?
Motley Fool - Aug 9, 2016
While the report included sales of Momenta's and partner Novartis AG's (NYSE:NVS) Glatopa, the generic version of Teva Pharmaceutical Industries' (NYSE:TEVA) once-daily Copaxone, investors should focus on the potential approval of the generic ...
Momenta Pharmaceuticals Inc. (MNTA) Stock Rating Reaffirmed by Stifel Nicolaus
The Cerbat Gem - Nov 29, 2016
Momenta Pharmaceuticals logo Momenta Pharmaceuticals Inc. (NASDAQ:MNTA)'s stock had its “positive” rating reiterated by investment analysts at Stifel Nicolaus in a report released on Tuesday.
Momenta Pharmaceuticals Inc. (MNTA) PT Set at $6.00 by Maxim Group - BBNS
The Momenta Pharmaceuticals Inc. (MNTA) Set to Announce Quarterly Earnings on ... - DailyQuint